← All trials
NCT07295418
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 23, 2023
- Primary completion
- Apr 22, 2025
- Completion date
- May 8, 2025
- First posted
- Dec 19, 2025
- Last posted
- Dec 19, 2025
- Enrollment
- 618
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Lead sponsor
- Government of ChinaCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.